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http://www.biomedcentral.com/1741-7015/11/137RESEARCH ARTICLE Open AccessNeuromuscular electrical stimulation for
preventing skeletal-muscle weakness and
wasting in critically ill patients:
a systematic review
Nicola A Maffiuletti1*, Marc Roig2,3, Eleftherios Karatzanos4 and Serafim Nanas4Abstract
Background: Neuromuscular electrical stimulation (NMES) therapy may be useful in early musculoskeletal
rehabilitation during acute critical illness. The objective of this systematic review was to evaluate the effectiveness
of NMES for preventing skeletal-muscle weakness and wasting in critically ill patients, in comparison with usual care.
Methods: We searched PubMed, CENTRAL, CINAHL, Web of Science, and PEDro to identify randomized controlled
trials exploring the effect of NMES in critically ill patients, which had a well-defined NMES protocol, provided
outcomes related to skeletal-muscle strength and/or mass, and for which full text was available. Two independent
reviewers extracted data on muscle-related outcomes (strength and mass), and participant and intervention
characteristics, and assessed the methodological quality of the studies. Owing to the lack of means and standard
deviations (SDs) in some studies, as well as the lack of baseline measurements in two studies, it was impossible to
conduct a full meta-analysis. When means and SDs were provided, the effect sizes of individual outcomes were
calculated, and otherwise, a qualitative analysis was performed.
Results: The search yielded 8 eligible studies involving 172 patients. The methodological quality of the studies was
moderate to high. Five studies reported an increase in strength or better preservation of strength with NMES, with
one study having a large effect size. Two studies found better preservation of muscle mass with NMES, with small
to moderate effect sizes, while no significant benefits were found in two other studies.
Conclusions: NMES added to usual care proved to be more effective than usual care alone for preventing
skeletal-muscle weakness in critically ill patients. However, there is inconclusive evidence for its benefit in
prevention of muscle wasting.
Keywords: Muscle strength, Muscle mass, Quadriceps femoris, Intensive care, Sepsis, RehabilitationBackground
A large majority of patients admitted to the intensive
care unit (ICU) after the very acute phase of a critical
illness exhibit major defects in skeletal-muscle strength
(weakness) and mass (wasting) [1-3]. This so-called
ICU-acquired weakness (ICUAW) is generally defined as
a bilateral deficit of muscle strength in all limbs [4],
which is accompanied by a profound loss of muscle
mass (as high as 5% per day during the first week of* Correspondence: nicola.maffiuletti@kws.ch
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reproduction in any medium, provided the orICU stay [5,6]), and is associated with delayed weaning
from mechanical ventilation [7], protracted and costly
stays in ICU and hospital stay (the average daily ICU
cost being approximately €1,000 [8]), and high mortality
rates [9,10]. ICUAW, whose etiology is multi-factorial, is
associated with impaired physical function and health
status in patients who have spent time in ICU, which
can persist even years after hospital discharge [11,12]. This
drastically increases the duration of post-ICU treatments
(including rehabilitation), and provokes severe social,
psychological, and economic consequences (the average
cost per life-year gained being approximately €6,000ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physical self-sufficiency and return to work of people
who have been critically ill.
Because early rehabilitation/mobilization in the ICU
has been shown to enhance short-term and potentially
long-term functional outcomes [13-15], the use of physical-
therapy strategies to counteract skeletal-muscle weakness
and wasting has been promoted frequently in the past
few years [16-20]. Neuromuscular electrical stimulation
(NMES), a technique that consists of generating visible
muscle contractions with portable devices connected to
surface electrodes [21], has been shown to be effective
in treating impaired muscles [22] as it has the potential to
preserve muscle-protein synthesis and prevent muscle
atrophy during prolonged periods of immobilization [23].
ICU-based NMES has recently been introduced for the
treatment of ICUAW, as it does not require active patient
cooperation, has an acute beneficial systemic effect on
muscle microcirculation [24], and seems to provide some
structural and functional benefits to critically ill patients
[25]. However, owing to the heterogeneity of the critically
ill patient group and also of the NMES procedures
implemented in ICUs [18,26-28], the effectiveness of this
rehabilitation procedure for ICUAW prevention remains
to be clearly proven.
Previous reviews have analyzed the effect of NMES on
different muscle outcomes in patients with specific
chronic diseases such as chronic obstructive pulmonary
disease (COPD) [22]. Since those reviews were published,
several randomized controlled trials (RCTs) have been
completed. Furthermore, a detailed analysis of the effects
of NMES in critically ill patients is lacking. Results from
previous studies suggest that the most deconditioned
patients obtain the best results when NMES is applied
[22]. Given the potential use of NMES among patients
with a limited capacity to engage in voluntary muscle
work, assessment of the evidence for the use of NMES in
critically ill patients is urgently needed. We therefore
undertook a formal systematic review of the literature to
determine the rehabilitative effect of NMES on skeletal-
muscle strength and mass in critically ill patients, in
comparison with standard care.
Methods
Electronic search and information sources
Although we developed a review protocol and followed
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines (see Additional file 1)
[29], the study protocol was not registered. Two of the
authors (EK, SN) independently performed the electronic
search on the following databases: PubMed (1951 to
present), Cochrane Controlled Trials Register (CENTRAL)
(1894 to present), Cumulative Index to Nursing and Allied
Health Literature (CINAHL) (1981 to present), Web ofScience (1970 to present) and Physiotherapy Evidence
Database (PEDro) (1929 to present). Reference lists from
articles related to the topic were also searched. The search
was not language-restricted but it was limited to
RCTs completed on human subjects. The terms used
to perform the search were: electrotherapy, electrical stimu-
lation, electrical muscle stimulation, electromyostimulation,
electrostimulation, neuromuscular stimulation, and NMES.
The results of the primary search were combined with the
terms: critically ill patients, critical illness, intensive care,
and ICU. For instance, these terms were combined as
follows to build the search in PubMed: (electrotherapy OR
electrical stimulation OR electrical muscle stimulation
OR electromyostimulation OR electrostimulation OR
neuromuscular stimulation OR NMES) AND (critically
ill patients OR critical illness OR intensive care OR
ICU). As additional filters, clinical trial (in ‘Article types’)
and humans (in ‘Species’) were chosen. The latest
electronic search was performed on March 3, 2012.Study selection and eligibility criteria
The list of titles and abstracts of articles retrieved in the
electronic search were first reviewed independently by
two of the authors (EK, NAM), who selected only those
potentially relevant for a more detailed review at full-text
level. Both reviewers then read the full text and applied
the following inclusion criteria: RCTs 1) exploring the
effect of NMES in critically ill patients; 2) with a
well-defined NMES protocol (that is, the main stimulation
parameters were provided) for at least one intervention
group; 3) with NMES applied to skeletal muscles with an
intensity equal to or greater than motor threshold (that
is, evoking a visible muscle contraction); 4) including
outcomes related to muscle strength and/or mass; (5)
and whose full text was available. After reviewing the
articles and applying the inclusion criteria independently,
both reviewers held a consensus meeting to compare their
results and decide which articles should finally be
included in the review. In cases of disagreement, a third
reviewer (MR) was included in the discussion to reach a
final consensus.Data collection process
Two of the authors (EK, MR) independently extracted
the data from the studies included in the review. Data
retrieved included characteristics of patients (number,
gender, age, diagnosis, and disease severity), interventions
(type, duration, frequency, and NMES parameters), and
muscle-related outcomes. When provided, details on the
number of patients excluded or discharged and their
compliance with treatment were also recorded. After
extraction, both reviewers compared their data-extraction
sheets to confirm the accuracy of the data.
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Two authors (EK and MR independently) assessed the
methodological quality of the studies using the PEDro
scale. This scale, which has been used extensively in the
methodological evaluation of similar studies [22], and has
previously shown good validity and reliability [30,31], is
based on 11 items for assessing scientific rigor: eligibility
criteria, random allocation, concealed allocation, baseline
comparability, blinded subjects, blinded therapists, blinded
assessors, follow-up, intention-to-treat (ITT), between-
group analysis, both point estimates, and variability. Ten
of the items were used in this study to calculate the final
score (maximum 10 points). The one item not used was
eligibility criteria, which was excluded because it affects
external but not internal or statistical validity. We compiled
an arbitrary scale of quality, based on PEDro score, with
high quality being a score greater than 5, moderate quality
being 4 or 5, and low quality being 3 or lower [32]. To
minimize errors and potential biases in the methodological
evaluation, both reviewers compared their scores in a
consensus meeting. In cases of disagreement, a third
reviewer (NAM) was included in the discussion to reach
a final consensus. Consistency between the two reviewers
who performed the methodological assessment (PEDro
scores) was evaluated with the Cronbach’s coefficient α.
Overall methodological quality based on the PEDro scores
was also categorized in accordance with the indications
provided by Van Tulder et al. [33].
Data analysis
Outcomes were grouped into two main categories for data
analysis: muscle strength and muscle mass (thickness
and volume). Probably because data were not normally
distributed, the majority of the studies included in the
review reported continuous outcomes using medians
with interquartile range instead of means with standard
deviation (SD). We used several statistical approaches
[34] in an attempt to normalize data distribution for the
three studies that had raw data available [25,35,36], but
we failed to alter the skewed data distribution. We also
used the equations proposed by Hozo et al. to estimate
means and SDs from medians, range, and sample size
[37]. However, none of these approaches allowed us to
calculate means and SDs reliably. In addition, because
of the critical status of some of the study participants,
muscle strength was not assessed at admission, and there-
fore baseline strength measurements were not obtained in
two studies [35,36]. Given these two important limitations,
it was not possible to pool the data from the different
studies to conduct a full meta-analysis. Instead, when
means and SDs were provided, we calculated the effect
size (d) of individual outcomes by dividing the difference
between mean change scores (post-intervention minus
pre-intervention scores) by the pooled SD [38]. Effect sizeswere then categorized in accordance with the criteria
established by Cohen as large (d> 0.8), moderate (d< 0.8
but > 0.2), or small (d< 0.2) effects [38]. When means
and SDs at baseline and after the intervention were not
provided, individual effect sizes were not calculated and,
instead, a qualitative analysis of the data was performed.
Results
Study selection
The different steps of the electronic search are illustrated
in Figure 1. The initial search yielded 461 articles, which
were included in the review process at abstract level. After
113 duplicates were removed and 348 records were
screened, only ten full-text articles could be assessed for
eligibility (336 records were excluded because they did not
meet all the required inclusion criteria, and two further
studies were excluded because they were conference
proceeding abstracts and the full text was not available
[39,40]). Of those ten articles, two were excluded; one was
not an RCT [41], and the other did not report any relevant
muscle-related outcome [42]. Finally, the remaining eight
RCTs met all the required criteria and were included in
the systematic review [25,35,36,43-47]. It should be noted,
however, that one of the selected articles [35] presented
a secondary analysis of the same study reported in
another article [36]; however, because these two studies
reported data from different outcomes, we presented them
individually [35,36].
Methodological quality
The PEDro score for each study is reported in Table 1.
The mean ± SD PEDro score of the studies included in
the review was 5.5 ± 1.5, with scores ranging from 4 to 8
(that is, moderate to high quality). When PEDro scores
of the two reviewers were compared, consistency was
high (α=0.751; P<0.0001) [48]. The most common
methodological weaknesses of the studies referred to
the blinding of patients (although sham NMES was used
in two studies [43,44], which could be considered a type
of blinding), therapists, and assessors. The allocation of
subjects to different intervention groups was concealed
in only two studies [43,46]. In addition, two studies did
not report baseline data for muscle strength, and therefore
comparability between groups could not be established
[35,36]. Only three studies met the follow-up criteria as
established by the PEDro scale [43,45,46], either because
data for at least one key outcome were not obtained in
more than 15% of the patients initially allocated into
treatment groups [25,35,36], or because the number of
patients from whom key outcome data were obtained
was not explicitly stated [44,47]. Two of the studies used
ITT analysis [35,36], and in one study all patients received
treatments as allocated [46]. The rest of the studies did
not meet the ITT analysis criterion [25,43-45,47]. The
Figure 1 Flow diagram of search strategy.
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NMES on muscle strength supported the effectiveness of
this intervention. Because two of these studies [43,46]
were of high methodological quality (PEDro score ≥ 7),
the level of evidence could be categorized as moderate to
strong. By contrast, because only two [25,44] of the four
studies that investigated the effect of NMES on muscle
mass found a positive outcome, the evidence in support of
this technique to improve muscle mass can be considered
as conflicting.Table 1 Methodological quality of the studies included in the
Abdellaoui et al.
2011 [42]
Gerovasili et al.
2009 [25]
Gruther et al.
2010 [43]
Karatz
et al. 2
Random
allocation
✓ ✓ ✓ ✓
Concealed
allocation
✓
Baseline
comparability
✓ ✓ ✓
Blinded
subjects
✓ ✓
Blinded
therapists
Blinded
assessors
✓ ✓
Follow-up ✓
Intention-to-
treat
✓
Between-group
analysis
✓ ✓ ✓ ✓
Point estimates
and variability
✓ ✓ ✓ ✓
Total score 7/10 5/10 6/10 4/10
PEDro, Physiotherapy Evidence Database.Participants
Characteristics of the patients included in the review are
shown in Table 2. We included in the review (at the
study level) only that information on patients for whom
data for at least one of the outcomes of interest was
provided. Data from 172 patients (46 female, 126 male)
were retrieved. Of those 172 patients, 74 were allocated to
the NMES group and 76 to the control group, while the
remaining 22 patients received NMES on one side of the
body and the contralateral side acted as control. The mostsystematic review (PEDro scores)
anos
012 [34]
Poulsen et al.
2011 [44]
Rodríguez et al.
2011 [45]
Routsi et al.
2010 [35]
Zanotti et al.
2003 [46]
✓ ✓ ✓ ✓
✓
✓ ✓ ✓
✓ ✓
✓ ✓
✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
6/10 8/10 4/10 4/10
Table 2 Characteristics of the patients included in the systematic review
Study Sample sizea
(% men)
Age, yearsb Diagnoses Disease severityb
SAPS III SOFA APACHE III Other
Abdellaoui et al. [42] C: 6 (100%) C: 67(59–72) COPD C: FEV1 of 15(10–27)%
N: 9 (78%) N: 59(57–69) N: FEV1 of 25(17–41)%
Gerovasili et al. [25] C: 13 (62%) C: 56(19) Sepsis C: 61(14) C: 8(3) C: 18(6)
N: 13 (46%) N: 59(23) Trauma N: 66(9) N: 10(3) N: 19(3)
Neurologic
Gruther et al. [43] C(A): 9 (89%) C(A): 48(12) Polytrauma
N(A): 8 (88%) N(A): 52(10) Cardiovascular
C(L): 8 (50%) C(L): 64(8) Transplant
N(L): 8 (88%) N(L): 61(10) Pneumonia
Cancer
Karatzanos et al. [34]
and Routsi et al. [35]
C: 28 (79%) C: 59(21) Sepsis C: 58(14) C: 8(3) C: 19(5) C: 39% with CIPNM
N: 24 (79%) N: 55(20) Trauma N: 55(11) N: 8(3) N: 16(4) N: 13% with CIPNM
Post-surgery
Brain injury
Respiratory failure
Poulsen et al. [44] C/N: 8 (100%) C/N: 67(64–72) Sepsis C/N: 11(9–14) C/N: 25(20–29) C/N: 13(10–22) days
in ICU
Rodríguez et al. [45]c C/N: 14 (50%) C/N: 72(63–80) Sepsis C/N: 10(9–12) C/N: 20(18–27) C/N: 27(19–44) days
in ICU
Zanotti et al. [46] C: 12 (67%) C: 65(4) COPD C: 47(19) days in ICU
N: 12 (75%) N: 66(8) N: 52(15) days in ICU
A, acute; APACHE III, Acute Physiology and Chronic Health Evaluation III; C, control group; CIPNM, critical illness polyneuromyopathy; COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in 1 second; ICU, intensive care unit; L, long-term; N, neuromuscular electrical stimulation group; SAPS III,
Simplified Acute Physiology Score III; SOFA, Sequential Organ Failure Assessment.
aOnly patients included in the analysis of the outcomes of interest are shown.
bData are provided as means (standard deviation) or medians (interquartile range).
cThe contralateral side acted as control.
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and trauma, although patients were also hospitalized
because of neurological problems, cancer, or post-surgery
complications. The severity of the disease was categorized
by the Simplified Acute Physiology Score III (SAPS III)
[25,35,36], the Sequential Organ Failure Assessment
(SOFA), and the Acute Physiology and Chronic Health
Evaluation II (APACHE II) [25,35,36,45,46]. No severity
scores were reported in one study [44]. In addition, two
studies reported the number of patients diagnosed with
critical illness polyneuromyopathy [35,36], and three other
studies reported the number of days in the ICU [45-47].
Two studies that investigated the effects of NMES on
patients with COPD reported spirometry and blood gas
values as measures of disease severity [43,47]. According
to international guidelines [49], those patients would be
categorized as patients with severe to very severe COPD.
Interventions
The characteristics of the interventions are shown in
Table 3. The duration of the NMES protocol ranged
from 7 days to 6 weeks. Patients in the control group
received usual care and, in some studies, either assistedlimb mobilization with [43] or without sham NMES
[47], or sham NMES alone [44]. NMES was delivered
while the patient was relaxed, and targeted the following
muscle groups: glutei [47], quadriceps [25,35,36,43-47],
hamstrings [43], peroneus longus [25,35,36], and biceps
brachii [46]. Specific details of the stimulation parameters
are shown in Table 3. In all studies, the criterion to establish
the minimum intensity of NMES was a visible muscle
contraction, which corresponds to the motor threshold
[50]. NMES intensity during the treatment was progres-
sively adjusted to the individual patient’s tolerance or set
as a percentage (150%) of the motor threshold [45].
Stimulation frequencies ranged from 8 to 100 Hz, and
pulse durations from 250 to 400 μs. Five studies reported
the use of symmetric biphasic pulses [25,35,36,43,46], and
one reported the use of asymmetric currents [47]. The
shape (rectangular) of the stimulation pulse and the
ramp-up and ramp-down times were reported in only
three studies [35,36,45]. In general, compliance (percentage
of sessions completed) with NMES treatment was high
(81 to 100%), but compliance was not reported in two
studies [44,47]. No adverse events or complications in
relation to NMES safety or tolerability were reported in
Table 3 Intervention characteristics, outcomes and main results of the studies included in the systematic review
Study Interventions by group/side NMES parameters Outcomesa (tools) Main results
C N
Abdellaoui et al. [42] ALM + sham NMES to quadriceps
and hamstrings
ALM + NMES to quadriceps and
hamstrings (BL): 60 min/day × 5
days/week × 6 weeks
Frequency: 35 Hz Muscle strength
(dynamometry)
Quadriceps strength increased more for
N than C (p < 0.01)Pulse duration: 400 μs
Intensity: 15-32 mA for quadriceps,
22-47 mA for hamstrings (start-end)
Gerovasili et al. [25] Usual care Usual care + NMES to quadriceps
and peroneus longus (BL): 55
min/day × 8 days
Frequency: 45 Hz Muscle thickness (US) Rectus femoris and vastus intermedius
(right side) thickness decreased less
for N than C (p < 0.05); d = 0.11-0.39
(small-moderate)
Pulse duration: 400 μs
On-off ratio: 12-6 s
Intensity: 37-38 mA (mean)
Gruther et al. [43] Sham NMES NMES to quadriceps (BL): 30-60
min/day × 5 days/week × 4 weeks
Frequency: 50 Hz Muscle thickness (US) Quadriceps thickness increased only
for N (long-term patients) (p < 0.13);
d = 0.36 (moderate)
Pulse duration: 350 μs
On-off ratio: 8-24 s
Intensity: tolerance
Karatzanos et al. [34] Usual care Usual care + NMES to quadriceps
and peroneus longus (BL):
55 min/day × 7 days/week
until ICU discharge
Frequency: 45 Hz Muscle strength (MRC) MRC scores for wrist flexion, hip flexion,
ankle dorsiflexion (p < 0.05) and knee
extension (p < 0.01) were greater for
N than C
Pulse duration: 400 μs
On-off ratio: 12-6 s
Intensity: motor threshold
Poulsen et al. [44] Contralateral side acted
as control
NMES to quadriceps (UL): 60
min/day × 7 days
Frequency: 35 Hz Muscle volume (CT) Quadriceps volume decreased for both
C and N, with no difference between
sides (p = 0.1)
Pulse duration: 300 μs
On-off ratio: 4-6 s
Intensity: motor threshold
+50% (adjusted daily)
Rodríguez et al. [45] Contralateral side acted
as control
NMES to biceps brachii and
quadriceps (UL): 2 × 30
min/day × 13 days
Frequency: 100 Hz Muscle strength (MRC) MRC scores for elbow flexion (p = 0.005)
and knee extension (p = 0.034) were
greater for N than C. Biceps thickness
was unchanged
Pulse duration: 300 μs
On-off ratio: 2-4 s Muscle thickness (US)
Voltage: 20-200 V
Routsi et al. [35] Usual care Usual care + NMES to quadriceps
and peroneus longus (BL):
55 min/day × 7 days/week
until ICU discharge
Frequency: 45 Hz Muscle strength (MRC) Global MRC score was greater for N
than C (p = 0.04)Pulse duration: 400 μs
On-off ratio: 12-6 s
Intensity: motor threshold
Zanotti et al. [46] ALM: 5 days/week × 4 weeks ALM + NMES to quadriceps
and glutei (BL): 25-30
min/day × 5 days/week × 4 weeks
Frequency: 8-35 Hz Muscle strength (MRC) MRC score increased more for N than
C (p < 0.02); d = 1.44 (large)Pulse duration: 250-350 μs
Intensity: motor threshold
ALM, active limb mobilization; BL, bilateral; C, control group; MRC, Medical Research Council; N, NMES group; NMES, neuromuscular electrical stimulation; US, ultrasonography.
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review [45]. For the remaining study, superficial skin
burns and excessive pain occurred in one and two
patients, respectively, out of fourteen patients treated by
Rodriguez et al. [46].
Outcomes
Muscle strength
Five studies assessed the effects of NMES on strength of
different muscle groups (Table 3) [35,36,43,46,47]. Four
studies evaluated muscle strength using the Medical
Research Council (MRC) scale [35,36,46,47]. One study
found a significantly larger MRC score increase in the
NMES group compared with the control group [47],
with a large effect size (d = 1.44). Two studies reported
greater MRC scores in the NMES group than in the control
group [35,36], although baseline measurements were
not provided. Another study found significantly higher
MRC scores on the stimulated side compared with the
contralateral side [46]. One study, in which quadriceps
muscle strength was assessed by dynamometry [43],
reported a significantly larger strength increase in the
NMES group compared with the control group.
Muscle mass
Four studies assessed the effects of NMES on muscle
thickness [25,44,46], or volume [45] (Table 3). Muscle
thickness was measured with ultrasonography, and muscle
volume was obtained from the analysis of computed
tomography images. In one study, muscle thickness
decreased less in the NMES group than in the control
group [25], and effect sizes (d) ranged from 0.11 to 0.39,
depending on the muscle group assessed. Another study
investigated the effects of NMES on quadriceps muscle
thickness in acute (less than 7 days hospitalization) and
long-term (greater than 14 days hospitalization) patients,
and found that thickness increased only for long-term
patients (d = 0.36) but not for acute or sham patients [44].
The two other studies found no significant changes in
muscle thickness between the stimulated and contralateral
biceps brachii [46], and no differences in muscle volume loss
between the stimulated and contralateral quadriceps [45].
Discussion
Neuromuscular electrical stimulation added to usual care,
in comparison with usual care alone or sham stimulation,
was associated with better muscle-strength outcomes in
patients in the ICU, with moderate to strong evidence.
However, the level of evidence was weaker and conflicting
for outcomes related to muscle mass, with small to
moderate effect sizes or no effect. These findings suggest
that NMES may have the potential to prevent skeletal-
muscle weakness in critically ill patients, which could
confer many important physical, psychosocial, andeconomic benefits for these patients after discharge from
ICU. However, it remains to be ascertained whether
NMES therapy can also prevent the muscle wasting
associated with critical illness.
The high inconsistency in ICU patient characteristics
between studies was not unexpected (as attested by
non-normal data distribution and lack of means and SDs),
but it affected the methodological quality of the included
studies, which prevented us from completing a meta-
analysis. Therefore, the main results of this systematic
review could only be interpreted with a thorough
qualitative analysis. Although it is extremely challenging
to perform large and well-controlled RCTs in this patient
population, future NMES studies should consider stratifying
patients for main diagnosis and eventually also for disease
severity, as this latter feature has been identified as an
independent risk factor for ICUAW incidence [10,51]. It is
conceivable that the benefits of NMES are greater for
patients admitted to the ICU with respiratory complications
(as suggested by the large effect sizes for patients with
COPD) [47], or neurological complications, compared
with patients with sepsis or trauma. For example,
inflammation-mediated electrolyte changes and also edema
may seriously affect conductivity and thus electrical
current diffusion [52], which could lessen any systemic
effect of NMES in these patient samples.
The questionable validity and heterogeneity of the
NMES protocol characteristics adopted in the eight studies
included in this systematic review further complicated the
interpretation of the present results. The strength of the
contraction induced by NMES (that is, evoked tension),
which is the main determinant of NMES effectiveness
[53], was not reported in any of the included studies.
Quantifying this parameter, rather than stating simple
current intensity/voltage, is crucial as it would also permit
discrimination of responders from non-responders [54,55],
and eventually allows ascertainment of the optimal NMES
characteristics for patients in the ICU on an individual
basis. In addition, evoked tension should be maximized,
whenever possible, by selecting appropriate current
parameters (stimulation frequency of 50 to 100 Hz [56] and
highest tolerable stimulation intensity, while minimizing
fatigue with long relaxation phases), joint position (long
muscle length), and methodological precautions such as
the accurate determination of muscle motor points [57].
Assessing voluntary muscle strength in the ICU is
extremely difficult. Despite potential limitations of manual
muscle testing such as poor validity and inaccuracy of
subjective ratings [58,59], especially when assessors are
not blinded, evaluation of voluntary strength using the
MRC score was used in the majority of the included RCTs,
and only one study used dynamometry [43]. Considering
the limited or absent cooperation of patients at admission
into the ICU, and the considerable influence of central
Maffiuletti et al. BMC Medicine 2013, 11:137 Page 8 of 10
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[60], it would be preferable if evaluation of muscle function
in these patients relied on artificially-evoked muscle
responses. Therefore, alternative methods that are inde-
pendent of patient cooperation such as peripheral magnetic
stimulation (which can also be used to evaluate respiratory
muscle function) [61], electrical impedance myography
[62], myotonometry [63], and mechanomyography [64],
would improve the validity of muscle testing in ICU.
The major risk factors for ICUAW are immobilization,
multiple organ failure, systemic inflammatory response
syndrome, gram-negative septicemia [10], hyperglycemia
[3,65], and medications such as aminoglycosides, colistin,
and corticosteroids. All these elements should be viewed as
important confounding factors that might distort accurate
interpretations of our findings. For example, patients with
a recent exacerbation of COPD (most of whom are
prescribed corticosteroids, which can induce myopathy)
were excluded in one instance [47], whereas another study
examined the effects of NMES after COPD exacerbation
(some patients received corticosteroids) [43]. Studies must
always carefully control for immobilization days, disease
severity scores (organ specific and physiological), and
medication use.
Even though physical-therapy practices vary widely
between different ICUs, there is growing interest in early
rehabilitation strategies that have the potential to pre-
vent skeletal-muscle weakness and wasting in critically
ill patients [20]. These interventions range from passive
stretching [5] and early mobilization therapy [3] to bedside
cycling ergometry [13]. Interestingly, NMES added to usual
care has recently been shown to be effective in reducing
ICUAW incidence [36]. The present systematic review
confirms these preliminary findings, highlighting the
potential role of NMES as a preventive countermeasure
against ICUAW. Compared with other rehabilitation
strategies, the unique aspects of NMES are that it is
relatively cost-effective (one multiple-user NMES unit costs
less than €400), does not require patient cooperation
(it can be applied to sedated patients) or stable cardiac
or respiratory function, can be implemented during
the first few days after ICU admission, and provokes
considerable central effects, both acute and chronic [66],
which could also contribute to preventing the occurrence
of muscle weakness in critically ill patients. Moreover, in
addition to muscle-related outcomes, NMES has been
shown to be more effective than conventional care or sham
stimulation for improving pulmonary function [36,43,47],
including accelerated weaning from mechanical ventilation
[36], physical function (6-minute walking distance [43]
and bed to chair transfer [47]), and for reducing the
incidence of critical illness polyneuromyopathy [36].
However, the effects of NMES on the pathophysiological
mechanisms of ICUAW are poorly known, and NMEScannot be easily used with all critically ill patients (for
example, those with skin lesions, traumatic fractures,
complete lower motor-neuron lesions and cardiac
pacemakers), so that there is still no consensus among
intensive care specialists about its real value.
Limitations
The major limitation of the present review concerns the
unavailability of outcome data (for example, baseline
strength measurements) to allow a full meta-analysis to
be conducted. At face value, this lack of data could be
indicative of reporting bias at outcome level. However,
rather than reporting bias, lack of outcome data should
simply be seen as one of the many limitations inherent
in studies conducted on patients admitted to the ICU.
We factorized potential biases at study level by assessing
the methodological quality of the studies, which allowed
us to assess the reliability and validity of the data
and to weigh the results of each study based on its
methodological rigor. Unfortunately, because of the
impossibility of calculating the effect sizes in many of the
studies included in the review, the risk of publication bias
could not be assessed.
Conclusions
This systematic review provides evidence that adding
NMES therapy to usual care is more effective than usual
care alone or sham NMES in preventing ICUAW.
Nevertheless, there is inconclusive evidence about the
effectiveness of NMES for the preservation of muscle
mass in ICU patients. The effects of NMES we found
were probably underestimated because of the non-
stratification of patients according to main diagnosis and
disease severity. More studies are needed to explore the
long-term effects of NMES therapy during ICU stay on
physical function and quality of life in ICU survivors, in
order to identify the optimal NMES dosage for ICUAW
prevention (both in terms of frequency, intensity and
volume), and to describe the feasibility, safety, and
cost-effectiveness of NMES in different subpopulations
of critically ill patients.
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